Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by whippeton Feb 02, 2017 12:59pm
131 Views
Post# 25790104

price going lower

price going lower
Might be great time to buy cheap stock...?  trading at .16 with not much on the bid. 
taking advantage of weakness.   
Cant wait to see those Q3 results.  I expect to see a small profit (about  $100T) . The important thing here is that it will confirm  a turn around for ADK. 
The AI technology by itself is worth $$$ . 
and the fact that we are working on a new application that will evaluate the risk of cardiovascular issues increases th potential of new streams of revenues in the mid term. 
In the mean time, the fact that people are waiting for Q3 results and other news, the bids slowly disappear and nervous people start unloading. which is great  ....   that's what makes a market.

Have a good day and GLTA
Bullboard Posts